Select a medication above to begin.
Adult Dosing .
Dosage forms: INJ
diphtheria, tetanus and pertussis prevention
- [primary (off-label)]
- Dose: 0.5 mL IM x2 doses at least 4wk apart, then 0.5 mL IM x1 dose 6-12mo later; Info: for patients who did not previously complete DT or DTaP vaccine series; may substitute w/ Td vaccine if Tdap vaccine used for at least 1 dose; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [booster, non-pregnant patients]
- Dose: 0.5 mL IM q10y; Info: search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [booster, pregnant patients]
- Dose: 0.5 mL IM x1 at 27-36 wk gestation; Info: search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
tetanus-prone wound management
- [0.5 mL IM x1 dose]
- Info: for patients who received 3 or more doses of tetanus-toxoid-containing vaccine if >5y since last dose; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ
diphtheria, tetanus and pertussis prevention
- [primary, 7 yo and older (off-label)]
- Dose: 0.5 mL IM x2 doses at least 4wk apart, then 0.5 mL IM x1 dose 6-12mo later; Info: for patients who did not previously complete DT or DTaP vaccine series; may substitute w/ Td vaccine if Tdap vaccine used for at least 1 dose; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [booster, 11 yo and older, non-pregnant patients]
- Dose: 0.5 mL IM x1 at 11-12 yo, then q10y; Info: search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [booster, 11 yo and older, pregnant patients]
- Dose: 0.5 mL IM x1 at 27-36 wk gestation; Info: search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
tetanus-prone wound management
- [7 yo and older]
- Dose: 0.5 mL IM x1 dose; Info: for patients who received 3 or more doses of tetanus-toxoid-containing vaccine if >5y since last dose; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- encephalopathy w/in 7 days after prior pertussis vaccine use
- caution: Arthus-type hypersensitivity rxn w/ prior tetanus vaccine
- caution: Arthus-type hypersensitivity rxn w/ prior diphtheria vaccine
- caution: Guillain-Barre syndrome w/in 6wk after prior tetanus vaccine use
- caution: neurologic disorder, progressive
- caution: neurologic disorder, unstable
- caution: seizures, uncontrolled
- caution: encephalopathy, progressive
- caution: immunocompromised patients
- caution: illness, acute moderate-severe
Drug Interactions .
Overview
diphtheria/tetanus/pertussis vaccine
vaccine
- non-live vaccine
Avoid/Use Alternative
- interferon gamma 1b
Monitor/Modify Tx
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- ado-trastuzumab emtansine
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atezolizumab
- atidarsagene autotemcel
- avelumab
- avutometinib
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- belatacept
- belimumab
- belinostat
- belzutifan
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- capecitabine
- capmatinib
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- cladribine oral
- clofarabine
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- defactinib
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dordaviprone
- dostarlimab
- doxorubicin
- dupilumab
- durvalumab
- duvelisib
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etrasimod
- everolimus
- fam-trastuzumab deruxtecan
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- ipilimumab
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lurbinectedin
- lymphocyte immune globulin, anti-thymocyte globulin
- margetuximab
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- nelarabine
- nemolizumab
- nilotinib
- nipocalimab
- nivolumab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- palbociclib
- panobinostat
- peginterferon alfa 2a
- pembrolizumab
- pentostatin
- pertuzumab
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- prednisolone
- prednisone
- procarbazine
- regorafenib
- retifanlimab
- rilonacept
- ripretinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sirolimus topical
- spesolimab
- sunitinib
- sunvozertinib
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- tralokinumab
- tremelimumab
- triamcinolone
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vandetanib
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanidatamab
- zanubrutinib
- zenocutuzumab
- zongertinib
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn, incl. Arthus-type
- anaphylactoid rxn
- anaphylaxis
- brachial neuritis
- Guillain-Barre syndrome
- encephalopathy
- myocarditis
- seizures
- facial palsy
- Henoch-Schonlein purpura
Common Reactions
- injection site rxn
- headache
- myalgia
- muscle weakness
- fatigue
- rigors
- nausea
- vomiting
- diarrhea
- abdominal pain
- arthralgia
- lymphadenopathy
- fever
- rash
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Look/Sound-Alike Drug Names
Boostrix confused with: Infanrix; Pediarix
tetanus/reduced diphtheria toxoids and acellular pertussis vaccine (Tdap) confused with: diphtheria/tetanus toxoids and acellular pertussis vaccine (DTaP)
Tdap confused with: DT; DTaP; Td
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy, recommended for every pregnancy at 27-36 wk gestation; no known risk of fetal harm based on human data
Pregnancy Registry
enroll patients or encourage patients to enroll in Boostrix Pregnancy Registry at 1-888-452-9622
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm not expected based on vaccine properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: unknown
Subclass: Diphtheria/Tetanus/Pertussis Vaccines ; Routine Adult Vaccines ; Routine Pediatric Vaccines
Mechanism of Action
exact mechanism of action unknown; induces antibody formation
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: GlaxoSmithKline
DEA/FDA: Rx
Retail Price
Estimated prices only. For current pricing, visit GoodRx.
intramuscular suspension:
- 5 units/2.5 units/18.5 mcg/0.5 mL (1 syringe, 0.5 mL): $48.00
intramuscular suspension:
- 5 units/2.5 units/18.5 mcg/0.5 mL (1 vial, 0.5 mL): $48.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.